US approves first vaccine against chikungunya virus: Drug regulator | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
July 23, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JULY 23, 2025
US approves first vaccine against chikungunya virus: Drug regulator

Health

BSS/AFP
10 November, 2023, 09:50 am
Last modified: 10 November, 2023, 10:24 pm

Related News

  • Govt moves to buy 2.2 lakh tonnes of US wheat 
  • World Health Organization raises concern about spread of mosquito-borne Chikungunya virus
  • Chikungunya spreads rapidly in Chattogram, 7 in 10 infected as authorities remain silent  
  • 'A trap': Asylum seekers arrested after attending US courts
  • Bangladesh holds inter-ministerial meeting on proposed US Trade Deal

US approves first vaccine against chikungunya virus: Drug regulator

BSS/AFP
10 November, 2023, 09:50 am
Last modified: 10 November, 2023, 10:24 pm
FILE PHOTO: A Ugandan health worker prepares to administer the ebola vaccine to a man in Kirembo village, near the border with the Democratic Republic of Congo in Kasese district, Uganda, June 16, 2019. REUTERS/James Akena/
FILE PHOTO: A Ugandan health worker prepares to administer the ebola vaccine to a man in Kirembo village, near the border with the Democratic Republic of Congo in Kasese district, Uganda, June 16, 2019. REUTERS/James Akena/

The US health authorities on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging global health threat."

The vaccine, developed by Europe's Valneva which will be marketed under the name Ixchiq, was approved for people 18 and over who are at increased risk of exposure, the FDA said.

Ixchiq's green-light by the US drug regulator is expected to speed the vaccine's rollout in countries where the virus is most prevalent.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Chikungunya, which causes fever and severe joint pain, is most prevalent in tropical and subtropical regions of Africa, southeast Asia and part of the Americas.

"However, chikungunya virus has spread to new geographical areas causing a rise in global prevalence of the disease," the FDA said, reporting more than 5 million cases in the past 15 years.

"Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions," senior FDA official Peter Marks said in a statement.

"Today's approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options."

The vaccine is injected in one dose and contains a live, weakened version of the chikungunya virus, as is standard with other vaccines.

Two clinical trials were carried out in North America on 3,500 people. Headache, fatigue, muscle and joint pain, fever and nausea were commonly reported side effects.

Serious reactions were reported in 1.6% of Ixchiq recipients in the trials, with two requiring hospitalisation.

USA

chikungunya / Vaccine / US

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • The meeting is being held at the chief adviser’s official residence Jamuna. Photo: CA Press Wing
    CA Yunus holding meeting with 13 political parties
  • NIBPS Director Dr Nasir Uddin speaks at a press briefing, 22 July, 2025. Photo: TBS
    Milestone tragedy: 8 out of 44 patients in critical condition at burn institute
  • Hasnat Abdullah. Photo: Collected
    Health adviser should resign, obvious example of CA’s nepotism: Hasnat

MOST VIEWED

  • Screengrab/Video collected from Facebook
    CCTV footage shows how Air Force jet nosedived after technical malfunction
  • Photo: Collected
    Bangladeshi man jailed for life in UK for murdering wife in front of their baby
  • Why Bangladesh's capital market is poised for a bull run
    Why Bangladesh's capital market is poised for a bull run
  • ISPR clarifies crashed plane was battle aircraft, not training jet
    ISPR clarifies crashed plane was battle aircraft, not training jet
  • Photo: Syed Zakir Hossain/TBS
    Secretariat protest: 75 injured in police-protester clash over edu adviser's resignation for delaying HSC rescheduling
  • Exim Bank's former chairman Nazrul Islam Majumder being taken to court on 22 July 2025. Photo: Collected
    Will repay all money if granted bail, won’t run away, ex-Exim Bank chair Nazrul tells court

Related News

  • Govt moves to buy 2.2 lakh tonnes of US wheat 
  • World Health Organization raises concern about spread of mosquito-borne Chikungunya virus
  • Chikungunya spreads rapidly in Chattogram, 7 in 10 infected as authorities remain silent  
  • 'A trap': Asylum seekers arrested after attending US courts
  • Bangladesh holds inter-ministerial meeting on proposed US Trade Deal

Features

Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

1d | Panorama
Photo: TBS

Mourning turns into outrage as Milestone students seek truth and justice

19h | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

1d | Panorama
Despite all the adversities, girls from the hill districts are consistently pushing the boundaries to earn repute and make the nation proud. Photos: TBS

Ghagra: Where dreams rise from dust for Bangladesh women's football

2d | Panorama

More Videos from TBS

80 Columbia University students punished for pro-Palestinian protest

80 Columbia University students punished for pro-Palestinian protest

1h | TBS World
Education Ministry dispute leads to delay in postponing exams

Education Ministry dispute leads to delay in postponing exams

2h | TBS Today
Trump announces massive trade deal with Japan

Trump announces massive trade deal with Japan

4h | TBS World
Six unidentified bodies are yet to be identified

Six unidentified bodies are yet to be identified

5h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net